AstraZeneca reports 42 percent lower death risk: October 30 results test AstraZeneca stock

Published on 10/26/2026 at 09:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The VOLGA trial cut recurrence risk 49 percent on October 24, 2026. AstraZeneca stock faces October 30 results after 42 percent lower death risk.

Oncology pipeline and timing

VOLGA reduced the risk of death by 42 percent on October 24, 2026.
At two years, 64 percent of patients were alive and event-free versus 45 percent in the comparator arm.
AstraZeneca's 9M and third-quarter results are scheduled for October 30, 2026.

Pop-Art-Comicbild eines Wissenschaftlers mit Spritze und Impfstofffläschchen — AstraZeneca plc (ISIN GB0009895292) prägt mit Impfstoffen und Medikamenten die globale Gesundheitsversorgung und Onkologie-Behandlung, Illustration mit AI erstellt.

AstraZeneca (ISIN GB0009895292) reported a 42 percent reduction in the risk of death in the VOLGA Phase III bladder-cancer trial on October 24, 2026. According to AstraZeneca, the combination of Imfinzi and enfortumab vedotin also reduced the risk of recurrence by 49 percent versus standard care.

VOLGA strengthens oncology evidence

The trial enrolled 695 patients with muscle-invasive bladder cancer who were ineligible for or had declined cisplatin-based chemotherapy. At two years, 64 percent of patients receiving the combination were alive and event-free, compared with 45 percent in the comparator arm.

Overall survival also favored the combination. Two-year survival reached 78 percent, versus 69 percent with standard treatment. The result gives AstraZeneca additional clinical evidence for Imfinzi as the company presents new oncology data at ESMO 2026.

What does the result mean for growth?

The commercial test is the conversion of trial evidence into additional indications and sales. AstraZeneca's investor-relations calendar lists an ESMO Meet the Management event for October 26, 2026, with oncology commentary scheduled at 2:30 p.m. Eastern Time. The company said its ESMO program includes more than 100 abstracts and five pivotal Phase III trials in a release dated October 19, 2026, according to AstraZeneca.

Three milestones frame the story

On October 15, 2026, AstraZeneca announced an insitro collaboration with USD 40 million upfront and potential milestone payments of up to USD 1.5 billion, as reported by MarketBeat. The October 24 VOLGA results then supplied a late-stage clinical milestone. The October 26 ESMO event is the latest scheduled management date.

Results date sets the next test

AstraZeneca's investor-relations calendar schedules its 9M and third-quarter 2026 results for October 30, 2026. Those figures will show whether the oncology pipeline progress is translating into reported revenue and management commentary.

At Tradegate, AstraZeneca stood at EUR 154.55 on October 26, 2026 at 8:26 a.m. CET. The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.